Bruised by a punishing Opdivo failure, Bristol-Myers looks to shake up the business, accelerate R&D
Fresh off one of the biggest clinical trial setbacks of the year, Bristol-Myers Squibb $BMY is planning to regroup and accelerate on the R&D side …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
